24 results
8-K
EX-99.1
IXHL
Incannex Healthcare Limited
30 Sep 24
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
4:01pm
, listing of common stock on Nasdaq, and expanded U.S. operations.
Research and development (R&D) expenses were for $12.9 million USD for the twelve … ,
Assets
Current assets:
Cash and cash equivalents
Prepaid expenses and other assets
R&D tax incentive receivable
Total current assets
Property, plant
10-K
2024 FY
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
drug candidates;
estimates regarding market size and related future growth rates;
our research and development (“R&D”) activities, including clinical … to support our development and ultimate global commercial objectives. We are monitoring the results of our R&D programs to identify new intellectual
S-1/A
IXHL
Incannex Healthcare Limited
17 Jul 24
IPO registration (amended)
8:47am
.”
Consolidated Statement of Profit or Loss and Other Comprehensive Income
Year endedJune 30,
Nine months endedMarch 31,
(in $’000, except share amounts)
R&D tax … research and development activities (“R&D”) and move our drug candidates into later stages of development. The process of carrying out the development
S-1
IXHL
Incannex Healthcare Limited
3 Jul 24
IPO registration
6:29am
,
(in $’000, except share amounts)
R&D tax incentive
Foreign exchange expense
Interest income
Research and development
Acquisition of in-process research … to incur substantial and increasing losses for the next several years as we expand our research and development activities (“R&D”) and move our drug
8-K
EX-99.1
7w9ljtcvw7 qipvm3
16 Apr 24
Incannex Healthcare Inc. Quarterly Update, Q1 2024
9:30am
10-Q
c0dej2u
14 Feb 24
Quarterly report
6:16am
6-K
EX-99.1
7pcr2vn
26 Oct 23
Incannex Healthcare September 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
6:02am
6-K
EX-99.1
29vuhs
1 Sep 23
Report of Foreign Private Issuer
12:00am
6-K
EX-99.1
bfew7u7hoiqhyr6p
27 Jul 23
Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
8:47pm
6-K
EX-99.1
i5b1k
18 May 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
rb8lnt8jnzlbhavj65p3
3 May 23
Report of Foreign Private Issuer
6:05am
6-K
EX-99.1
uke3 9de7b1
26 Apr 23
Incannex Healthcare March 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
9:40pm
6-K
EX-99.1
d27g84cm
5 Dec 22
Report of Foreign Private Issuer
6:01am
20-F
vcjfv pn63x29fatmt
28 Oct 22
Annual report (foreign)
6:31am
6-K
EX-99.1
12j1aj rkc
19 Sep 22
Report of Foreign Private Issuer
9:38pm
6-K
EX-99.1
4a8 4kf7k7llr
1 Sep 22
Report of Foreign Private Issuer
6:13am
6-K
EX-99.1
he5z uu2k
9 Aug 22
Report of Foreign Private Issuer
6:01am
6-K
EX-99.1
rof2fdu7ptrz
2 Aug 22
Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A
6:06am